$0.02
(1.85%)
Add to watchlist
Create an alert
Stocks and Shares ISAAEON Biopharma, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on developing its botulinum toxin complex, ABP-450 (prabotulinumtoxinA) injection or ABP-450, for debilitating medical conditions, with an initial focus on the neuroscience market. ABP-450 is a 2-chain polypeptide, a heavy chain joined by a bond to a light chain. ABP-450 interferes with nerve impulses by inhibiting the release of acetylcholine into the neuromuscular junction, causing a flaccid paralysis of muscles. The active biologic ingredient in ABP-450 is Clostridium botulinum toxin, type A with a complete molecular complex weight of 900 kDa. Its initial development programs for ABP-450 are directed at migraine, cervical dystonia, gastroparesis and post-traumatic stress disorder (PTSD). The Company has completed enrollment and dosing of patients for a Phase II double blind study of ABP-450 for the treatment of both chronic and episodic migraine.
Company Information
About this company
Key people
Robert Bancroft
President, Chief Executive Officer, Director
Jennifer Sy
Principal Financial Officer, Chief Accounting Officer
Alex Wilson
Executive Vice President, Chief Legal Officer, Corporate Secretary
Chad Oh
Chief Medical Officer
Jost Fischer
Independent Chairman of the Board
Marc Forth
Director
Seongsoo Park
Director
Eric Carter
Independent Director
Robert J. Palmisano
Independent Director
Click to see more
Key facts
- Shares in issue12.11m
- EPICAEON
- ISINUS00791X2099
- LocationUnited States
- SectorHealthcare
- IndustryBiotechnology & Drugs
- Market cap$13.07m
- Employees5
- ExchangeNyse American LLC
- Index
- Website
Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Overview data is sourced from Refinitiv.